VivoSeq
Oncology

Neoplasm

5

Pipeline Programs↗

7

Active Trials↗

5

Companies Involved↗

Neoplasm is an early-stage landscape with 5 programs across 5 companies. The most active players are EMD Serono, Novartis, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 2Novartis logo

Novartis

1 program

PreclinicalPfizer logo

Pfizer

1 program

PreclinicalK

Karyopharm Therapeutics Inc

1 program

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

11

clinical trials

Completed3 · 27%
Recruiting3 · 27%
Active, not recruiting2 · 18%
Unknown status1 · 9%
Enrolling by invitation1 · 9%
Not yet recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
Recruiting·—·N/A·NCT06474533·199 enrolled
Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Recruiting·UUniversity of California, Irvine·Phase 2·NCT07693452·15 enrolled
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Recruiting·SSt. Jude Children's Research Hospital·Preclinical·NCT06239272·139 enrolled
Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD
Active, not recruiting·National Cancer Center, Korea·Phase 3·NCT02407119·470 enrolled
A Prospective, Randomized, Single-blinded Study Evaluating the Effect of Frozen-Section Directed Excision on Positive Surgical Margins in High-grade Vulvar Dysplasia
Active, not recruiting·WWake Forest University Health Sciences·Preclinical·NCT05934851·112 enrolled
Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol
Not yet recruiting·CCity of Hope Medical Center·N/A·NCT07691008·1,200 enrolled
Overseas Care and Cancer Survivorship in Small Island Developing States of the Eastern Caribbean
Enrolling by invitation·Vaughan A. Lewis Institute for Research and Innovation·N/A·NCT07695116·900 enrolled
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00092534·12,167 enrolled
Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue
Completed·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00005927·690 enrolled
SBRT With Immunotherapy for Mesothelioma
Completed·MMayo Clinic·Phase 1·NCT04926948·20 enrolled
Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
Unknown status·UUniversity of Zurich·Phase 1/2·NCT02528526·69 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)